Regeneus Ltd (ASX: RGS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Regeneus Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Regeneus Ltd (ASX: RGS)
Latest News
No posts found.
RGS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Regeneus Ltd
Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus,across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.
RGS Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
27 Mar 2024 | $0.01 | $0.00 | 0.00% | 206,029 | $0.01 | $0.01 | $0.01 |
22 Mar 2024 | $0.01 | $0.00 | 0.00% | 125,000 | $0.01 | $0.01 | $0.01 |
21 Mar 2024 | $0.01 | $0.00 | 0.00% | 70,193 | $0.01 | $0.01 | $0.01 |
20 Mar 2024 | $0.01 | $0.00 | 0.00% | 468,948 | $0.01 | $0.01 | $0.01 |
15 Mar 2024 | $0.01 | $0.00 | 0.00% | 1,000 | $0.01 | $0.01 | $0.01 |
13 Mar 2024 | $0.01 | $0.00 | 0.00% | 220,000 | $0.01 | $0.01 | $0.01 |
07 Mar 2024 | $0.01 | $0.00 | 0.00% | 10,000 | $0.01 | $0.01 | $0.01 |
04 Mar 2024 | $0.01 | $0.00 | 0.00% | 433,634 | $0.01 | $0.01 | $0.01 |
29 Feb 2024 | $0.01 | $0.00 | 0.00% | 1 | $0.01 | $0.01 | $0.01 |
28 Feb 2024 | $0.01 | $0.00 | 0.00% | 20,641 | $0.01 | $0.01 | $0.01 |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Barry George Sechos | Non-Executive DirectorNon-Executive Chairman | Jul 2012 |
Mr Sechos has served on the Board since 2012 and has over 35 years experience as a director, business executive with experience in investment and asset management. Barry is Executive Director of the Sherman Group (an early-stage investor in the Company) and sits on the board of many Sherman Group companies and investee companies. His previous directorship includes Concentrated Leaders Fund Ltd (resigned 31 August 2021) and Phoslock Environmental Technologies Ltd (resigned 5 September 2023).
|
Professor Graham Vesey | Chief Scientific OfficerExecutive Director | Aug 2007 |
Mr Vesey is a biotechnology entrepreneur, technology innovator and inventor. Graham was a co-founder and Executive Director of the successful biotech company, BTF, which was sold to bioMerieux in 2007. Graham is an Adjunct Professor at Macquarie University.
|
Mr Leo Lee | Non-Executive Director | Jan 2019 |
Mr Lee brings more than 20 years experience in pharmaceutical innovation, commercialisation, regulation and policy development and has worked in North America and Asia. Mr Lee currently serves as Country President, Japan, for Novartis and prior to his CEO role at Regeneus, he was President, Japan, for Merck KGaA. Prior to this, he served as President, Japan, for Allergan plc, a global pharmaceutical company. Leo has held sales and commercial roles in Merck & Co., IQVIA and Accelrys, Inc.
|
Mr Karolis Rosickas | Chief Executive Officer | Nov 2020 |
-
|
Ms Hang Ling (Helen) Leung | Company Secretary | Jul 2021 |
-
|
Karolis Rosickas | Chief Executive Officer |
-
|
|
Hang Ling (Helen) Leung | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Hsbc Custody Nominees (Australia) Limited | 32,103,469 | 14.26% |
Bnp Paribas Nominees Pty Ltd | 27,065,582 | 7.95% |
Citicorp Nominees Pty Limited | 21,655,145 | 7.06% |
Mrs Julia Caroline Hughes | 13,648,692 | 4.47% |
I Rom Group Co Ltd | 9,144,043 | 2.98% |
Sunreef Pty Ltd | 8,907,834 | 2.25% |
Super Dino Pty Ltd | 8,805,740 | 1.72% |
Dr Paul Francis Morton | 5,345,031 | 1.70% |
Mr Thomas Georg Mechtersheimer | 5,255,519 | 1.59% |
Mr Simon Clarkson | 5,216,726 | 1.31% |
Bnp Paribas Noms Pty Ltd | 4,806,797 | 0.99% |
MLB Holdings Pty Ltd | 4,000,000 | 0.84% |
Bubbling Wells Pty Ltd | 2,500,000 | 0.82% |
Mcguire Family Holdings Pty Ltd | 2,350,000 | 0.77% |
Liddle Investments Group Pty Ltd | 2,202,859 | 0.72% |
Dr Marc Ronald Wilkins | 2,020,676 | 0.66% |
Kbross Pty Ltd | 2,000,000 | 0.65% |
The Quist Group Pty Ltd | 1,760,608 | 0.57% |
Mark Timney | 1,750,000 | 0.57% |
Jeffrey Chun Kim Khoo | 1,750,000 | 0.57% |
Towns Corporation Pty Ltd | 1,675,000 | 0.54% |